Despite PD-L1 protein expression being used as a predictive marker of therapeutic response to PD-L1 inhibitors in several cancers [14,15,16,17], there are many cancers that fail to respond to anti-PD-1/PD-L1 therapies. This evidence concerns the gene CD274 and cancer.